TORONTO, ON–(Marketwired – July 11, 2016) – Titan Medical Inc. (TSX: TMD) (OTCQX: TITXF) is pleased to announce that its Director of Strategic Development and Intellectual Property, Jasminder Brar, has been recognized by Intellectual Asset Management (IAM) as a leading intellectual property strategist in the IAM Strategy 300 for the second consecutive year.
“Jasminder is a valued member of the senior management team and on behalf of the entire Titan organization we congratulate him on this recognition,” said John Hargrove, Chief Executive Officer. “As a leading IP strategist, we look forward to his continued contribution and strengthening Titan’s IP framework to maximize shareholder value.”
The IAM Strategy 300 is a unique guide that lists the individuals that in-depth research, undertaken by a team based in London, Washington DC and Hong Kong, has shown possess world-class skills in the development and roll-out of strategies that maximize the value of patents, copyright, trademarks and other IP rights. Not only does the publication feature world-class, third-party IP advisers, but it also includes individuals that work inside operating companies. This reflects the growing importance that businesses across the world attach to having in-house IP value creation expertise, alongside the legal expertise that has traditionally characterized corporate IP functions.
“The IP market is becoming increasingly international, with companies across the world now focusing on creating maximum value from the assets that they own. That makes IP strategists more important than they have ever been before,” says IAM editor Joff Wild. “We are delighted that this publication has become the recognized source of reference for those seeking to identify the men and women who offer best-in-class expertise. What’s more, we believe that the roles all those named in the IAM Strategy 300 play is only going to increase in importance over the coming years. We salute each and every one of them.”
The IAM Strategy 300 is available in printed format and online at www.IAM-media.com/strategy300.
About Intellectual Asset Management
Intellectual Asset Management (IAM) is produced in London by the IP Division of Globe Business Media Group and reports on intellectual property as a business asset. Its primary focus is on how intellectual property can be best managed and exploited to create corporate value. The publication’s core readership comprises senior executives in IP-owning companies, corporate counsel, private practice lawyers and attorneys, licensing and technology transfer managers, and investors and analysts. For more information, visit IAM’s website at www.IAM-media.com.
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”). The Company’s SPORT™ Surgical System, currently under development, includes a surgeon-controlled robotic platform that incorporates a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a surgeon workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and provides a 3D high-definition endoscopic view of inside a patient’s body. The SPORT™ Surgical System is designed to enable surgeons to perform a broad set of surgical procedures for general abdominal, gynecologic, and urologic indications. For more information, visit the Company’s website at www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 30, 2016 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
CONTACT INFORMATION
Titan Medical Inc.
John Hargrove
Chief Executive Officer
(416) 548-7522 (ext. 151)
john.hargrove@titanmedicalinc.com
www.titanmedicalinc.com
EVC Group, Inc.
Amanda Prior
Aprior@evcgroup.com
646-445-4800
Michael Polyviou
mpolyviou@evcgroup.com
646-445-4800